Welcome to our dedicated page for Cvrx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CVRx, Inc. (NASDAQ: CVRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. CVRx is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular diseases, and its filings offer detailed insight into the Barostim platform, financial performance and risk profile.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand revenue trends, gross margin, operating expenses, cash and cash equivalents, long-term debt and stockholders’ equity, as well as narrative discussions of the business and risk factors. These filings also describe CVRx’s focus on Barostim for heart failure, regulatory approvals such as FDA approval and CE Mark, and the importance of reimbursement and coding decisions to the company’s operations.
Current reports on Form 8-K document material events, including the release of quarterly financial results and key corporate developments. For example, CVRx has filed 8-Ks to furnish earnings press releases and to disclose the appointment of a Chief Operating Officer, along with details about compensation arrangements. Such filings help investors track significant changes in management, financing and operating plans.
Through this page, users can also access information related to CVRx’s capital structure, including term loan agreements secured by substantially all of the company’s assets, as described in its public communications. Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as revenue drivers, Barostim-related updates, reimbursement discussions and key risk disclosures. Real-time updates from EDGAR, along with AI explanations of 10-Ks, 10-Qs and 8-Ks, allow investors to follow how CVRx’s regulatory reporting reflects the evolution of its heart failure therapy business.
Johnson & Johnson filed a Form 4 reporting small open-market sales of CVRx, Inc. common stock held indirectly through its subsidiary Johnson & Johnson Innovation - JJDC, Inc. JJDC sold 500 CVRx shares on 11/21/2025 at a price of $10.00 per share and 2,200 shares on 11/24/2025 at a weighted average price of $10.06 per share. After these transactions, Johnson & Johnson, through JJDC, indirectly beneficially owned 4,047,198 CVRx common shares. The filing notes that the 11/24/2025 price reflects multiple trades between $10.00 and $10.10, and Johnson & Johnson undertakes to provide detailed trade breakdowns upon request.
Johnson & Johnson filed a Form 4 reporting open‑market sales of CVRx (CVRX)52,332 shares at a weighted average price of $10.21 on 11/06/2025 and 200 shares at $10.00 on 11/07/2025. After these transactions, J&J indirectly beneficially owned 4,050,898 CVRx shares through JJDC. Prices for the 11/06 trades ranged from $10.00 to $10.49 per share.
CVRx, Inc. filed a shelf registration statement on Form S-3 to offer and sell up to $150,000,000 of securities from time to time after effectiveness. The shelf covers common stock, preferred stock, debt securities, stock purchase contracts, warrants, rights, and units, with specific terms to be set in prospectus supplements.
Offerings may be made through underwriters, dealers, agents, or directly, at fixed, market-related, or negotiated prices. Use of proceeds will be described in the applicable supplement. CVRx’s common stock trades on Nasdaq under the symbol CVRX; on November 3, 2025, the last reported sale price was $10.36 per share.
CVRx, Inc. reported third‑quarter results showing steady top‑line growth and improved margins while remaining unprofitable. Revenue for the three months ended September 30, 2025 was $14.7 million, up 10% year over year, driven mainly by U.S. heart failure implants. Gross margin rose to 87% from 83% on higher average selling prices and manufacturing efficiencies.
Operating expenses were $25.0 million, yielding a loss from operations of $12.3 million. Net loss was $12.9 million (basic and diluted net loss per share $0.49). For the nine months, revenue reached $40.6 million (up 13%) with a net loss of $41.4 million.
Cash and cash equivalents were $85.1 million as of September 30, 2025, with $50.0 million of long‑term debt outstanding under the Innovatus loan. The company issued 543,462 shares via its ATM for gross proceeds of $9.5 million during the nine‑month period. CMS finalized the 2026 Medicare Physician Fee Schedule adding Category I CPT codes for Barostim, effective January 1, 2026.
CVRx, Inc. furnished a Form 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The disclosure was made under Item 2.02, and the press release is included as Exhibit 99.1 and incorporated by reference.
The company states this information is being furnished, not filed, under the Exchange Act. CVRx’s common stock trades on the Nasdaq Global Select Market under the symbol CVRX.
Brent Binkowski, Chief Operating Officer of CVRx (CVRX), acquired equity awards on 08/11/2025 that increase his direct stake in the company. He received 16,600 restricted stock units that vest 25% on each anniversary of the grant date, and was granted stock options for 74,900 shares with an exercise price of $7.51. The options vest 25% after one year and then 1/48th per month thereafter and have an expiration date listed as 08/10/2035. Following these transactions, the reporting person directly beneficially owns 16,600 shares and holds options for 74,900 shares.
Brent Binkowski, identified as Chief Operating Officer of CVRx, Inc. (CVRX), submitted an initial Form 3 reporting his relationship to the issuer as an officer. The Form 3 records that no securities are beneficially owned by Mr. Binkowski at the time of the reported event. The filing is an initial ownership disclosure required under Section 16 to report officers' holdings (or lack thereof).
FAQ
What is the current stock price of Cvrx (CVRX)?
What is the market cap of Cvrx (CVRX)?
